![Robert Smith](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: - $ in data 30/06/2026
Mr. Robert J.
Smith is an Independent Director at Citius Oncology, Inc. and an Independent Director at Citius Pharmaceuticals, Inc. He is on the Board of Directors at Citius Oncology, Inc., Citius Pharmaceuticals, Inc., Foundation For Cell & Gene Medicine and Alliance for Regenerative Medicine.
Mr. Smith was previously employed as a Senior Vice President-Global Gene Therapy Business by Pfizer Inc. and a Senior Vice President-Mergers & Acquisitions by Wyeth LLC.
He also served on the board at BioNJ, Inc., Life Sciences Pennsylvania, Ignite Immunotherapy, Inc. and Bamboo Therapeutics, Inc. He received his undergraduate degree from the University of Rochester and an MBA from the University of Rochester Simon Business School.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
-.--% | 22/05/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
| 13/02/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| CITIUS PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 12/03/2024 |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services Promotes legislative, regulatory and reimbursement initiatives for regenerative medicine | Direttore/Membro del Consiglio | 01/01/2018 |
Foundation For Cell & Gene Medicine
 Foundation For Cell & Gene Medicine Foundation For Cell & Gene Medicine is an independent international nonprofit organization established in 2018 by the Alliance for Regenerative Medicine, dedicated to advancing ethical cell and gene therapies, tissue-engineered products, and regenerative medicine. The private company is located in the US. Its mission is to accelerate patient access to safe, effective, and potentially curative therapies by educating patients, caregivers, healthcare professionals, policymakers, and the public. The foundation conducts programs focused on education, health and economic impact analysis, and infrastructure development for the adoption of these treatments. Key initiatives include the State Rare Disease Education Initiative (STRIDE), which provides patient-centered, state-specific education to improve access to innovative therapies for rare diseases; the Health & Economic Impact (HEI) program, which develops frameworks and economic models to demonstrate the value of cell and gene therapies; and the Infrastructure Program, which addresses logistical and healthcare system needs for widespread therapy adoption. The foundation also offers educational resources, a standardized nomenclature project, and outreach efforts such as webinars, social media campaigns, toolkits, and conferences. Its leadership and steering committees include experts from various fields such as industry, patient advocacy, health economics, communications, public policy, manufacturing, and precision medicine. | Direttore/Membro del Consiglio | 01/01/2019 |
| Società | Posizione | Fine |
|---|---|---|
| PFIZER INC. | Corporate Officer/Principal | 01/01/2024 |
Ignite Immunotherapy, Inc.
 Ignite Immunotherapy, Inc. BiotechnologyHealth Technology Designs and develops oncolytic virus vaccines | Direttore/Membro del Consiglio | 01/10/2019 |
Bamboo Therapeutics, Inc.
 Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops gene therapies for rare neuromuscular and central nervous system diseases | Direttore/Membro del Consiglio | 01/08/2016 |
Wyeth Corp.
 Wyeth Corp. Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes pharmaceuticals, vaccines & biotechnology products | Corporate Officer/Principal | 01/10/2009 |
BioNJ, Inc.
 BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services Promotes the biotechnology industry in New Jersey | Direttore/Membro del Consiglio | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 10 |
|---|---|
Wyeth Corp.
Wyeth Corp. Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes pharmaceuticals, vaccines & biotechnology products | Health Technology |
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Citius Pharmaceuticals, Inc.
 Citius Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Operates as a pharmaceutical company | Health Technology |
Life Sciences Pennsylvania
 Life Sciences Pennsylvania Miscellaneous Commercial ServicesCommercial Services Provides consulting services to biosciences industry | Commercial Services |
BioNJ, Inc.
BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services Promotes the biotechnology industry in New Jersey | Commercial Services |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services Promotes legislative, regulatory and reimbursement initiatives for regenerative medicine | Health Services |
University of Rochester Simon Business School
 University of Rochester Simon Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bamboo Therapeutics, Inc.
Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops gene therapies for rare neuromuscular and central nervous system diseases | Health Technology |
Ignite Immunotherapy, Inc.
Ignite Immunotherapy, Inc. BiotechnologyHealth Technology Designs and develops oncolytic virus vaccines | Health Technology |
Foundation For Cell & Gene Medicine
Foundation For Cell & Gene Medicine Foundation For Cell & Gene Medicine is an independent international nonprofit organization established in 2018 by the Alliance for Regenerative Medicine, dedicated to advancing ethical cell and gene therapies, tissue-engineered products, and regenerative medicine. The private company is located in the US. Its mission is to accelerate patient access to safe, effective, and potentially curative therapies by educating patients, caregivers, healthcare professionals, policymakers, and the public. The foundation conducts programs focused on education, health and economic impact analysis, and infrastructure development for the adoption of these treatments. Key initiatives include the State Rare Disease Education Initiative (STRIDE), which provides patient-centered, state-specific education to improve access to innovative therapies for rare diseases; the Health & Economic Impact (HEI) program, which develops frameworks and economic models to demonstrate the value of cell and gene therapies; and the Infrastructure Program, which addresses logistical and healthcare system needs for widespread therapy adoption. The foundation also offers educational resources, a standardized nomenclature project, and outreach efforts such as webinars, social media campaigns, toolkits, and conferences. Its leadership and steering committees include experts from various fields such as industry, patient advocacy, health economics, communications, public policy, manufacturing, and precision medicine. |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
